Work

A study on olfactory mucosa-derived stem cells for ischemic stroke is registered in Hainan

Year: 2026
Type: article
Abstract: On November 4, 2026, China announced that a study on autologous olfactory mucosa-derived mesenchymal stem cells for ischemic stroke was registered in Hainan. Initiated by Hainan Susheng Biotechnology Co., Ltd., the project lists Haikou People's Hospital as its clinical research institution. Olfactory mucosa-derived cells provide a distinct source for investigating immunomodulation and neural repair. A 2025 study of hypoxia-preconditioned cells reported reduced microglial ferroptosis and neuroinflammation and improved neurological outcomes in experimental stroke models. These findings provide a preclinical rationale; the registered product's preparation and its effects in humans need to be clinically evaluated. For Hainan, the project links local scientific work with collaboration between a biotechnology enterprise and a hospital. Its contribution will depend on appropriate patient selection, credible study design, meaningful functional outcomes, reproducible cell manufacture, and long-term safety monitoring. Transparent reporting can make this experience informative for future stroke research and the development of regulated regenerative medicine.
Language: English
Subfield: Cell Biology
Open Access status: diamond
OpenAlex ID: W7234991594
FWCI:
Cites: 3
Cited by:
Related to: 10